Inrig Jula 4

What Happened
Inrig Jula, Chief Medical Officer of Travere Therapeutics (TVTX), had a sell-to-cover sale and received equity awards. On 2026-01-31 Jula had 28,130 restricted stock units settle (acquired at $0.00) and was also granted/received 75,000 derivative awards (reported as $0.00). On 2026-02-03 Jula sold 6,956 shares in an open-market transaction at $32.12 per share for proceeds of $223,427. The sale was executed to satisfy tax withholding obligations related to the RSU settlement (see footnote).

Key Details

• Transaction dates: RSU settlement/grant on 2026-01-31; sale executed 2026-02-03. Filing accession: 0001902368-26-000003.
• Sale details: 6,956 shares sold at $32.12 each, total proceeds $223,427.
• Awards received: 28,130 RSUs settled; 75,000 derivative awards (RSUs/options depending on plan) granted at $0.00.
• Footnotes: F1 = each RSU converts to one share upon settlement; F2 = the sale was a mandatory "sell-to-cover" to fund tax withholding (not a discretionary sale by the insider); F3 = standard vesting schedule noted (one-fourth after 1 year, then monthly over 36 months) for stock option-style awards.
• Shares owned after transaction: not specified in the provided filing.
• Timeliness: Filing was submitted 2026-02-03 for transactions dated 2026-01-31 — appears to be timely (Form 4 is due within two business days).

Context
The RSU settlement and grant reflect compensation; the sale was a routine sell-to-cover to satisfy tax withholding and therefore does not necessarily indicate a voluntary decision to liquidate holdings. For retail investors, such mandated sales are common following equity compensation events and differ from discretionary insider selling.